Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05203549Unknown

Consistency Between Treatment Responses in PDO Models and Clinical Outcomes in Gastric Cancer

Role: lead

NCT04927611Unknown

Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm

Role: collaborator

NCT04906733Unknown

Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients.

Role: lead

All 3 trials loaded